Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Rusconi C, et al. Among authors: angelillo p. Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. Blood. 2022. PMID: 35789260 Free article.
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Ferreri AJM, Angelillo P, Erbella F, Cattaneo C, Verga L, Lleshi A, Allione B, Ponzoni M, Facchetti F, Pagani C, Foppoli M, Pecciarini L, Sassone M, Steffanoni S, Flospergher E, Rossi G, Spina M, Re A. Ferreri AJM, et al. Among authors: angelillo p. Blood Adv. 2022 Nov 22;6(22):5811-5820. doi: 10.1182/bloodadvances.2022007475. Blood Adv. 2022. PMID: 35580327 Free PMC article.
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation.
Ferreri AJM, Sassone M, Angelillo P, Zaja F, Re A, Di Rocco A, Spina M, Fabbri A, Stelitano C, Frezzato M, Volpetti S, Zambello R, Rusconi C, De Lorenzo D, Scarano E, Arcari A, Bertoldero G, Nonis A, Calimeri T, Perrone S, Cecchetti C, Tarantino V, Steffanoni S, Foppoli M, Ciceri F, Ponzoni M. Ferreri AJM, et al. Among authors: angelillo p. Hematol Oncol. 2020 Aug;38(3):257-265. doi: 10.1002/hon.2742. Epub 2020 May 5. Hematol Oncol. 2020. PMID: 32356913 Clinical Trial.
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Ferreri AJM, et al. Among authors: angelillo p. Blood Adv. 2020 Aug 11;4(15):3648-3658. doi: 10.1182/bloodadvances.2020002270. Blood Adv. 2020. PMID: 32766857 Free PMC article. Clinical Trial.
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.
Scarfò L, Ferrari S, Frustaci AM, Tani M, Bari A, Scarano E, Colia M, Ranghetti P, Angelillo P, Ronchi P, Ponzoni M, Ferreri AJM, Ghia P. Scarfò L, et al. Among authors: angelillo p. Blood Adv. 2022 Sep 27;6(18):5356-5359. doi: 10.1182/bloodadvances.2022007138. Blood Adv. 2022. PMID: 35613463 Free PMC article. Clinical Trial. No abstract available.
Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy.
Fominskiy EV, Scandroglio AM, Monti G, Calabrò MG, Landoni G, Dell'Acqua A, Beretta L, Moizo E, Ravizza A, Monaco F, Campochiaro C, Pieri M, Azzolini ML, Borghi G, Crivellari M, Conte C, Mattioli C, Silvani P, Mucci M, Turi S, Tentori S, Baiardo Redaelli M, Sartorelli M, Angelillo P, Belletti A, Nardelli P, Nisi FG, Valsecchi G, Barberio C, Ciceri F, Serpa Neto A, Dagna L, Bellomo R, Zangrillo A; COVID-BioB Study Group. Fominskiy EV, et al. Among authors: angelillo p. Blood Purif. 2021;50(1):102-109. doi: 10.1159/000508657. Epub 2020 Jul 13. Blood Purif. 2021. PMID: 32659757 Free PMC article.
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E, Diffidenti A, Finardi A, Gagliardi F, Anzalone N, Nonis A, Furlan R, De Lorenzo D, Terreni MR, Martinelli V, Sassone M, Foppoli M, Angelillo P, Guggiari E, Falini A, Mortini P, Filippi M, Tarantino V, Eoli M, Ciceri F, Doglioni C, Tripodo C, Locatelli M, Cangi MG, Ponzoni M. Ferreri AJM, et al. Among authors: angelillo p. Br J Haematol. 2021 May;193(3):497-505. doi: 10.1111/bjh.17357. Epub 2021 Feb 23. Br J Haematol. 2021. PMID: 33620087 Clinical Trial.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lang M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. Mastaglio S, et al. Among authors: angelillo p. Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29. Clin Immunol. 2020. PMID: 32360516 Free PMC article.
21 results